Parent's perception of respiratory syncytial virus and subsequent wheezing burden: A multi-country cross-sectional survey.
Humans
Respiratory Sounds
Cross-Sectional Studies
Respiratory Syncytial Virus Infections
/ epidemiology
Parents
/ psychology
Male
Female
Infant
Child, Preschool
Italy
/ epidemiology
Surveys and Questionnaires
Spain
/ epidemiology
United Kingdom
/ epidemiology
United States
/ epidemiology
Hospitalization
/ statistics & numerical data
Respiratory Syncytial Virus, Human
Adult
Child
Cost of Illness
asthma
bronchiolitis
caregivers
cross‐sectional survey
infant health
respiratory syncytial virus (RSV)
wheezing
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
14
05
2024
received:
25
03
2024
accepted:
15
05
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
ppublish
Résumé
Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. RSV bronchiolitis is associated with an increased risk of subsequent wheezing. We aimed to document the parents' perception of the link between RSV infection and subsequent wheezing, wheezing-related healthcare and family resources use, and its impact on family daily life. This cross-sectional online survey enrolled 1200 parents with at least one child ≤6y living in the United States, United Kingdom, Spain, and Italy. Children diagnosed with RSV bronchiolitis before age of 2 years were included in the RSV group, and those never diagnosed with RSV bronchiolitis in the Reference group. The odds of wheezing were 4.5-fold (95%CI 3.5-5.9) higher in the RSV than in the Reference group. The odds increased to 7.7-fold (95%CI 5.4-11.1) among children who were hospitalized, and 9-fold (95%CI 5.1-16.6) among those admitted to pediatric intensive care with RSV bronchiolitis. Similar trends were observed across all countries. In total, 57% of parents reported their child's wheezing to have moderate to severe impact on their emotional well-being, and 53% on their daily life activities and/or social life. 64% of parents reported moderate-severe impact of wheezing on child's quality of sleep and 49% and 46% reported a moderate-severe impact on their children's emotional well-being and physical activities. This survey suggests an association between RSV infection and subsequent wheezing in children across different countries. Wheezing, especially in association with RSV infection, was associated with increased healthcare utilization and costs, and significantly impacted parents' and children daily life.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. RSV bronchiolitis is associated with an increased risk of subsequent wheezing. We aimed to document the parents' perception of the link between RSV infection and subsequent wheezing, wheezing-related healthcare and family resources use, and its impact on family daily life.
METHODS
METHODS
This cross-sectional online survey enrolled 1200 parents with at least one child ≤6y living in the United States, United Kingdom, Spain, and Italy. Children diagnosed with RSV bronchiolitis before age of 2 years were included in the RSV group, and those never diagnosed with RSV bronchiolitis in the Reference group.
RESULTS
RESULTS
The odds of wheezing were 4.5-fold (95%CI 3.5-5.9) higher in the RSV than in the Reference group. The odds increased to 7.7-fold (95%CI 5.4-11.1) among children who were hospitalized, and 9-fold (95%CI 5.1-16.6) among those admitted to pediatric intensive care with RSV bronchiolitis. Similar trends were observed across all countries. In total, 57% of parents reported their child's wheezing to have moderate to severe impact on their emotional well-being, and 53% on their daily life activities and/or social life. 64% of parents reported moderate-severe impact of wheezing on child's quality of sleep and 49% and 46% reported a moderate-severe impact on their children's emotional well-being and physical activities.
CONCLUSIONS
CONCLUSIONS
This survey suggests an association between RSV infection and subsequent wheezing in children across different countries. Wheezing, especially in association with RSV infection, was associated with increased healthcare utilization and costs, and significantly impacted parents' and children daily life.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14169Subventions
Organisme : Else Care (Carenity)
Informations de copyright
© 2024 The Author(s). Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Jain H, Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection. StatPearls; 2023.
Suleiman‐Martos N, Caballero‐Vazquez A, Gomez‐Urquiza JL, Albendin‐Garcia L, Romero‐Bejar JL, Canadas‐De la Fuente GA. Prevalence and risk factors of respiratory syncytial virus in children under 5 years of age in the WHO European region: A systematic review and meta‐analysis. J Pers Med. 2021;11(5):416.
Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health. 2019;7(8):e1031‐e1045.
Stobbelaar K, Mangodt TC, Van der Gucht W, et al. Risk factors associated with severe RSV infection in infants: what is the role of viral Co‐infections? Microbiol Spectr. 2023;11(3):e0436822.
Wang X, Li Y, Vazquez Fernandez L, et al. Respiratory syncytial virus‐associated hospital admissions and bed days in children <5 years of age in 7 european countries. J Infect Dis. 2022;226(Suppl 1):S22‐S28.
Rha B, Curns AT, Lively JY, et al. Respiratory syncytial virus‐associated hospitalizations among young children: 2015–2016. Pediatrics. 2020;146(1):e20193611.
Munro APS, Martinon‐Torres F, Drysdale SB, Faust SN. The disease burden of respiratory syncytial virus in infants. Curr Opin Infect Dis. 2023;36(5):379‐384.
Gea‐Izquierdo E, Gil‐Prieto R, Hernandez‐Barrera V, Gil‐de‐Miguel A. Respiratory syncytial virus‐associated hospitalization in children aged <2 years in Spain from 2018 to 2021. Hum Vaccin Immunother. 2023;19(2):2231818.
Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047‐2064.
Zhang S, Akmar LZ, Bailey F, et al. Cost of respiratory syncytial virus‐associated acute lower respiratory infection Management in Young Children at the regional and global level: A systematic review and meta‐analysis. J Infect Dis. 2020;222(Suppl 7):S680‐S687.
Driscoll AJ, Arshad SH, Bont L, et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization‐sponsored meeting. Vaccine. 2020;38(11):2435‐2448.
McGinley JP, Lin GL, Öner D, et al. Clinical and viral factors associated with disease severity and subsequent wheezing in infants with respiratory syncytial virus infection. J Infect Dis. 2022;226(Suppl 1):S45‐S54.
van Wijhe M, Johannesen CK, Simonsen L, Jørgensen IM, Fischer TK. A retrospective cohort study on infant respiratory tract infection hospitalizations and recurrent wheeze and asthma risk: impact of respiratory syncytial virus. J Infect Dis. 2022;226(Suppl 1):S55‐s62.
Diez‐Domingo J, Perez‐Yarza EG, Melero JA, et al. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis. 2014;14:544.
Glaser EL, Hariharan D, Bowser DM, et al. Impact of respiratory syncytial virus on child, caregiver, and family quality of life in the United States: systematic literature review and analysis. J Infect Dis. 2022;226(Suppl 2):S236‐S245.
Fauroux B, Simoes EAF, Checchia PA, et al. The burden and long‐term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6(2):173‐197.
Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health‐related quality of life. Pediatr Infect Dis J. 2004;23(5):414‐417.
Raïs S, Radoszycki L, Dourgnon P, Rochaix L, Chekroun M. Accurate representation of patients' opinions for decision making: are online health communities good candidates? ISPOR 2017 (poster).
Di Sarno L, Curatola A, Conti G, et al. The effects of COVID‐19 outbreak on pediatric emergency department admissions for acute wheezing. Pediatr Pulmonol. 2022;57(5):1167‐1172.
Kouis P, Lemonaris M, Xenophontos E, Panayiotou A, Yiallouros PK. The impact of COVID‐19 lockdown measures on symptoms control in children with asthma: A systematic review and meta‐analysis of observational cohort studies. Pediatr Pulmonol. 2023;58(11):3213‐3226.
Scarponi D, Bedetti L, Zini T, et al. COVID‐19 restrictions and hygiene measures reduce the rates of respiratory infections and wheezing among preterm infants. Acta Biomed. 2023;94(1):e2023032.
Ullmann N, Allegorico A, Bush A, et al. Effects of the COVID‐19 pandemic and lockdown on symptom control in preschool children with recurrent wheezing. Pediatr Pulmonol. 2021;56(7):1946‐1950.
Ye D, Gates A, Radhakrishnan L, Mirabelli MC, Flanders WD, Sircar K. Changes in asthma emergency department visits in the United States during the COVID‐19 pandemic. J Asthma. 2023;60(8):1601‐1607.
Wang X, Li Y, Nair H, Campbell H. Time‐varying association between severe respiratory syncytial virus infections and subsequent severe asthma and wheeze and influences of age at the infection. J Infect Dis. 2022;226(Suppl 1):S38‐S44.
Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541‐545.
Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65(12):1045‐1052.
Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary prevention of asthma. Reviewing the evidence for early‐life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med. 2015;191(1):34‐44.
Rosas‐Salazar C, Hartert TV. Infant respiratory syncytial virus infection and childhood asthma: A shift in the paradigm? Clin Transl Med. 2023;13(9):e1414.
Carbonell‐Estrany X, Perez‐Yarza EG, Garcia LS, et al. Long‐term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants‐the SPRING study. PLoS One. 2015;10(5):e0125422.
Hoch H, Kattan M, Szefler SJ. Challenges in managing difficult‐to‐treat asthma in children: stop, look, and listen. Pediatr Pulmonol. 2020;55(3):791‐794.
Fawcett R, Porritt K, Stern C, Carson‐Chahhoud K. Experiences of parents and carers in managing asthma in children: a qualitative systematic review. JBI Database System Rev Implement Rep. 2019;17(5):793‐984.
Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics. 2005;115(6):1536‐1546.
Backman K, Piippo‐Savolainen E, Ollikainen H, Koskela H, Korppi M. Adults face increased asthma risk after infant RSV bronchiolitis and reduced respiratory health‐related quality of life after RSV pneumonia. Acta Paediatr. 2014;103(8):850‐855.
Garegnani L, Styrmisdottir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021;11(11):CD013757.
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants [press release]. 2022.
UK's MHRA approves Beyfortus (nirsevimab) to prevent RSV in infants. 2022. https://www.pharmaceutical‐business‐review.com/news/mhra‐approves‐beyfortus‐nirsevimab‐rsv‐infants
FDA approves Beyfortus™ (nirsevimab‐alip) to protect infants against RSV disease [press release]. 2023.
Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465‐1477.
Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion f protein vaccine in older adults. N Engl J Med. 2023;388(7):595‐608.
Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion f vaccine in pregnancy to prevent rsv illness in infants. N Engl J Med. 2023;388(16):1451‐1464.